TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Xvivo Perfusion AB
Closing information (x1000 NOK)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover | 392,830 | 251,984 | 188,423 |
Financial expenses | 52,681 | 19,704 | 13,072 |
Earnings before taxes | 21,107 | 6,500 | -59,989 |
EBITDA | 45,949 | -7,275 | |
Total assets | 1,639,346 | 1,504,374 | 1,205,065 |
Current assets | 442,222 | 533,965 | 485,280 |
Current liabilities | 127,600 | 101,929 | 75,687 |
Equity capital | 1,352,784 | 1,253,599 | 1,056,465 |
- share capital | 721 | 735 | 712 |
Employees (average) | 114 | 92 | 63 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency | 82.5% | 83.3% | 87.7% |
Turnover per employee | 3,446 | 2,739 | 2,991 |
Profit as a percentage of turnover | 5.4% | 2.6% | -31.8% |
Return on assets (ROA) | 4.5% | 1.7% | -3.9% |
Current ratio | 346.6% | 523.9% | 641.2% |
Return on equity (ROE) | 1.6% | 0.5% | -5.7% |
Change turnover | 148,419 | 76,579 | -42,927 |
Change turnover % | 61% | 44% | -19% |
Chg. No. of employees | 22 | 29 | 17 |
Chg. No. of employees % | 24% | 46% | 37% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.